Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trial
ALLO•Allogene Therapeutics said ALLO-329 improved skin scores in 8 of 10 assessed patients with skin-predominant systemic sclerosis in its Phase 1 RESOLUTION trial. Early safety findings showed no dose-limiting toxicities, and the company plans another data readout in 2027.
1. Preliminary trial results
Allogene Therapeutics announced preliminary results from its Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases. Most assessed patients with skin-predominant systemic sclerosis showed sustained skin improvement, including patients treated without lymphodepleting chemotherapy; most remained off background immunosuppressive therapy. Early safety findings showed no dose-limiting toxicities.
2. Next steps
The results are scheduled for presentation on November 9, 2026, at the American College of Rheumatology Convergence. Dose escalation continues to guide selection of a Phase 2 regimen, with the next data readout planned for 2027.
